Philip Morris International R&D, Philip Morris Products SA, Rue des Usines 56, CH-2000 Neuchâtel, Switzerland.
Philip Morris International R&D, Philip Morris Products SA, Rue des Usines 56, CH-2000 Neuchâtel, Switzerland.
Regul Toxicol Pharmacol. 2017 Nov;90:1-8. doi: 10.1016/j.yrtph.2017.08.006. Epub 2017 Aug 14.
There has been a sustained effort in recent years to develop products with the potential to present less risk compared with continued smoking as an alternative for adult smokers who would otherwise continue to smoke cigarettes. During the non-clinical assessment phase of such products, the chemical composition and toxicity of their aerosols are frequently compared to the chemical composition and toxicity of the smoke from a standard research cigarette - the 3R4F reference cigarette. In the present study, it is demonstrated that results of these analytical comparisons are similar when considering commercially available cigarette products worldwide. A market mean reduction of about 90% is observed on average across a broad range of harmful and potentially harmful constituents (HPHC) measured in the aerosol of a candidate modified risk tobacco product, the Tobacco Heating System 2.2 (THS2.2), compared against the levels of HPHC of cigarettes representative of selected markets; this mean reduction is well in line with the reduction observed against 3R4F smoke constituents in previous studies.
近年来，人们一直在努力开发潜在风险低于继续吸烟的产品，作为那些否则将继续吸烟的成年吸烟者的替代品。在这些产品的非临床评估阶段，其气溶胶的化学成分和毒性经常与标准研究香烟——3R4F 参考香烟的化学成分和毒性进行比较。在本研究中，证明当考虑全球范围内市售香烟产品时，这些分析比较的结果是相似的。与选定市场香烟中 HPHC 的水平相比，候选改良风险烟草产品——Tobacco Heating System 2.2（THS2.2）气溶胶中 HPHC 的测量值平均观察到约 90%的市场平均值降低；与之前研究中对 3R4F 烟雾成分的观察结果相比，这种平均值降低幅度相当。
